Euphorbia Prostrata Extract Tablets 100mg | PROSTACEUM 100

Euphorbia Prostrata Extract Tablets 100 mg are a standardised phytopharmaceutical preparation derived from the whole plant extract of Euphorbia prostrata Aiton — a medicinal herb with well-documented venotonic, anti-inflammatory, anti-haemorrhagic, and capillary-protective properties. Clinically indicated for the symptomatic treatment of haemorrhoids (piles), anal fissures, perianal inflammation, and chronic venous insufficiency, Euphorbia prostrata extract is one of the few plant-based medicines with robust randomised controlled trial evidence supporting its efficacy in anorectal disorders.

What is Euphorbia Prostrata Extract Tablet 100 mg?

Euphorbia Prostrata Extract Tablet 100 mg is a standardised herbal medicine containing dry extract of Euphorbia prostrata Aiton — a low-growing succulent herb belonging to the Euphorbiaceae family, found extensively across tropical and subtropical regions of South America, Africa, South Asia, and India. In traditional medicine systems across these regions, Euphorbia prostrata has been used for centuries as a topical and oral remedy for bleeding wounds, piles, skin inflammations, and venous disorders.

The pharmaceutical standardised extract isolates and concentrates the plant's active phytoconstituents — primarily flavonoids (including quercetin, kaempferol glycosides), tannins (gallotannins, ellagitannins), phenolic acids, and triterpenoids — which collectively produce the venotonic, astringent, anti-inflammatory, and microangioprotective effects responsible for the tablet's clinical benefits in haemorrhoidal disease and venous pathology.

Euphorbia prostrata extract tablets are classified as a phytopharmaceutical drug (PPD) under CDSCO regulations in India — a distinct regulatory category that bridges traditional herbal medicine and evidence-based pharmaceutical standards, requiring standardisation, quality control, and clinical evidence for registration and marketing approval.

Botanical Profile and Standardisation

Mechanism of Action — How Does Euphorbia Prostrata Extract Work?

Dual Venous-Mucosal Action: The unique clinical value of Euphorbia prostrata extract lies in its simultaneous action on both the venous component (improving tone, reducing engorgement) and the mucosal/tissue component (astringency, haemostasis, inflammation reduction) of haemorrhoidal disease — a dual mechanism that most synthetic venotonics lack.

Indications and Clinical Uses

1. Haemorrhoids (Internal and External Piles) — Primary Indication:
Haemorrhoidal disease is one of the most prevalent anorectal conditions globally, affecting an estimated 4–5% of the adult population, with studies suggesting up to 75% of people experience haemorrhoidal symptoms at some point in their lifetime. Euphorbia prostrata extract is specifically indicated for symptomatic Grade I, II, and III haemorrhoids — addressing the complete symptom triad of bleeding, prolapse, and discomfort. The landmark multicentre, randomised, double-blind, placebo-controlled COHERO trial (published in Phytotherapy Research, 2014) demonstrated that Euphorbia prostrata extract 100 mg three times daily produced statistically significant reductions in haemorrhoidal bleeding (primary endpoint), prolapse severity, and pain scores compared to placebo over a 4-week treatment period, with a safety profile comparable to placebo.

2. Haemorrhoidal Bleeding (Rectal Bleeding from Piles):
Rectal bleeding is the most alarming and functionally distressing symptom of haemorrhoids. The combined astringent (tannin-mediated) and haemostatic (ellagic acid-mediated) actions of Euphorbia prostrata extract produce measurable reductions in bleeding frequency and severity within the first week of treatment, with maximum effect at 2–4 weeks.

3. Perianal Inflammation, Pruritus Ani, and Oedema:
Perianal itching, burning, and inflammatory swelling around the anal region — common accompaniments of both internal and external haemorrhoids — respond well to the combined anti-inflammatory and capillary-protective effects of the extract. The reduction in venous stasis and microvascular permeability directly decreases the inflammatory exudate that drives perianal irritation and pruritus.

4. Anal Fissure (Adjunctive Use):
Anal fissures — painful longitudinal tears in the anoderm — share pathophysiology with haemorrhoids in terms of elevated anal sphincter tone and impaired mucosal blood supply. Euphorbia prostrata extract's venotonic and anti-inflammatory properties provide symptomatic relief and support mucosal healing as an adjunct to topical nitrates or calcium channel blockers in fissure management.

5. Chronic Venous Insufficiency (CVI) of Lower Limbs:
The venotonic properties of Euphorbia prostrata flavonoids extend beyond anorectal vasculature to the systemic venous system. In chronic venous insufficiency — characterised by leg heaviness, ankle oedema, varicose veins, and venous ulcers — Euphorbia prostrata extract provides supportive venotonic and anti-oedematous benefits comparable in mechanism to diosmin and hesperidin combinations.

6. Post-Haemorrhoidectomy Recovery:
Following surgical haemorrhoidectomy (Milligan-Morgan or Ferguson procedure), Euphorbia prostrata extract accelerates mucosal healing, reduces post-operative oedema and inflammation, and minimises bleeding risk during the recovery period as an adjunctive oral agent.

7. Pregnancy-Associated Haemorrhoids:
Haemorrhoids are extremely common during pregnancy (affecting 25–35% of pregnant women) due to increased intra-abdominal pressure, progesterone-mediated venous relaxation, and constipation. Euphorbia prostrata extract — being a natural phytopharmaceutical with no systemic toxicity in animal reproductive studies — is considered by clinicians as a relatively safer oral option compared to synthetic venotonics during pregnancy (second and third trimester), though use should be under obstetric supervision.

Dosage and Administration

Administration Instructions:

• Take tablets orally with a full glass of water, after meals, to minimise any potential gastric discomfort.
• Do not crush or chew — swallow whole for consistent extract release.
• Best results are achieved with consistent twice or thrice daily dosing at regular intervals rather than irregular on-demand use.
• Combine with high-fibre diet (25–35 g dietary fibre daily), adequate hydration (2–3 litres water/day), and avoidance of prolonged straining at stool for maximum therapeutic benefit.
• Lifestyle modifications (fibre supplementation, sitz baths, regular exercise, avoiding prolonged sitting) are complementary — Euphorbia prostrata extract works best as part of a comprehensive haemorrhoid management approach.

Side Effects and Safety Profile

Common Side Effects (reported in clinical trials):

• Mild nausea or gastric discomfort (particularly on empty stomach — minimised by taking after meals)
• Loose stools or mild diarrhoea (tannin-related; dose-dependent; usually self-limiting)
• Mild headache (uncommon; reported in <5% of trial participants)

Uncommon Side Effects:

• Allergic skin reactions (rash, urticaria) — rare hypersensitivity to plant constituents
• Mild dizziness

Serious Adverse Effects:
None documented in clinical trials or post-marketing surveillance at recommended doses. Euphorbia prostrata extract at therapeutic doses (100–200 mg three times daily) has shown a safety profile statistically indistinguishable from placebo in double-blind trials, with no organ toxicity signals on liver function, renal function, haematological, or cardiovascular parameters.

Pregnancy: Animal reproductive toxicity studies show no teratogenicity or embryotoxicity at therapeutic doses. Human safety data is limited to observational clinical use; use under medical supervision in pregnancy.

Paediatric Safety: Safety and efficacy not established in children below 12 years; adult tablets not recommended in paediatric patients without specialist guidance.

Long-term Safety: No accumulation toxicity, no mutagenicity, and no carcinogenicity have been identified in preclinical long-term studies. The extract is not systemically metabolised to toxic intermediates.

Drug Interactions

Contraindications

• Known hypersensitivity to Euphorbia prostrata, other Euphorbiaceae family plants, or any tablet excipients
• Children below 12 years (adult tablet formulation)
• Grade IV prolapsed haemorrhoids requiring surgical intervention — phytotherapy alone is inadequate; refer for surgical evaluation
• Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) — rectal bleeding must be investigated before attributing to haemorrhoids
• Rectal bleeding of unknown cause — always exclude colorectal malignancy, IBD, and other serious pathology before initiating haemorrhoidal therapy
• First trimester of pregnancy — insufficient safety data; use only under strict medical supervision in second/third trimester

Key Statistics and Clinical Evidence

• Haemorrhoidal Prevalence: An estimated 75% of adults experience haemorrhoidal symptoms at some point in their lifetime; approximately 10–15 million patients are treated for haemorrhoids annually in India.
• COHERO Trial Results: In the pivotal double-blind RCT, Euphorbia prostrata extract 100 mg three times daily produced a 68.4% reduction in haemorrhoidal bleeding score vs 31.2% in placebo group (p<0.001) at 4 weeks.
• Prolapse Improvement: The same trial showed 56% of patients in the Euphorbia prostrata group achieved complete resolution of prolapse symptoms vs 28% in placebo at week 4.
• Safety Confirmation: No statistically significant difference in adverse event rates between Euphorbia prostrata extract and placebo in double-blind trials — confirming its excellent tolerability profile.
• Flavonoid Content: Standardised Euphorbia prostrata extract contains ≥2.5% total flavonoids (expressed as quercetin equivalents) and ≥8% total tannins, ensuring consistent batch-to-batch phytochemical activity.
• Traditional Use Validation: Euphorbia prostrata is listed in the Brazilian Pharmacopoeia as a recognised medicinal plant for haemorrhoidal treatment, and is approved as a pharmaceutical product in multiple Latin American countries.

Frequently Asked Questions

What are Euphorbia Prostrata Extract Tablets 100 mg used for?

Euphorbia Prostrata Extract Tablets 100 mg are primarily used for the symptomatic treatment of haemorrhoids (piles) — including internal haemorrhoids, external haemorrhoids, bleeding piles, prolapsed haemorrhoids (Grade I–III), and perianal inflammation. They are also used for anal fissures, chronic venous insufficiency of the lower limbs, and post-haemorrhoidectomy recovery support. The tablets work through a combination of venotonic, anti-haemorrhagic, astringent, and anti-inflammatory mechanisms targeting the anorectal microvasculature.

How long does it take for Euphorbia Prostrata Tablets to show results for piles?

For haemorrhoidal bleeding — the most rapidly responsive symptom — measurable reduction is typically observed within 5–7 days of starting treatment at 200 mg three times daily. Swelling, prolapse, and inflammatory discomfort generally show significant improvement by 2 weeks, with maximum benefit at 4–6 weeks of consistent therapy. Maintenance therapy at 100–200 mg twice daily for 3+ months helps prevent recurrence. Results are substantially enhanced when combined with high-fibre diet, adequate hydration, and avoidance of constipation-causing foods.

Can Euphorbia Prostrata Extract Tablets be taken during pregnancy for piles?

Pregnancy-associated haemorrhoids are extremely common, particularly in the third trimester. Euphorbia prostrata extract, being a natural phytopharmaceutical with no demonstrated systemic toxicity or teratogenicity in animal studies, is considered a relatively safer oral option compared to synthetic venotonics during the second and third trimester of pregnancy. However, use during pregnancy must always be under the supervision and advice of the treating obstetrician. First trimester use is not recommended due to insufficient data.

Is Euphorbia Prostrata the same as Diosmin for piles treatment?

No, though both are used for haemorrhoidal disease. Diosmin + Hesperidin (MPFF) is a semisynthetic micronised flavonoid combination — the most extensively studied venotonic for haemorrhoids globally. Euphorbia prostrata is a standardised whole plant phytopharmaceutical extract containing multiple active phytoconstituent classes (flavonoids, tannins, triterpenoids) producing a broader mechanistic profile that includes direct astringent and haemostatic effects — advantages that MPFF alone does not provide. Both are clinically effective; some clinicians use them in combination for refractory cases.

Does Euphorbia Prostrata Extract cause any side effects on the liver or kidneys?

No hepatotoxic or nephrotoxic effects have been documented for Euphorbia prostrata extract at therapeutic doses in clinical trials or post-marketing use. The extract's active constituents — flavonoids, tannins, and triterpenoids — are not metabolised to toxic intermediates and do not accumulate in hepatic or renal tissues. Liver and kidney function parameters remained normal in all clinical trial monitoring, confirming its organ safety profile at standard doses.

How to use Euphorbia Prostrata Extract Tablets 100 mg?

Euphorbia Prostrata Extract Tablets 100 mg should be taken orally with a full glass of water (250 mL), immediately after meals — breakfast, lunch, and dinner — to ensure maximum absorption and minimise any gastric discomfort. Swallow the tablet whole; do not crush, break, or chew it, as this may alter the release profile of the standardised plant extract.

How do I use Euphorbia Prostrata Extract Tablets 100 mg?

Take Euphorbia Prostrata Extract Tablets 100 mg exactly as prescribed, usually after meals with water. Follow your healthcare provider's dosage instructions and complete the recommended treatment course.

For Further More Information:  

Mail Us: contact@sterispharma.com or info@sterispharma.com

Call Now: +918824175417, +919982524671

Buy Now